{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:04:18Z","timestamp":1791180258558,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T00:00:00Z","timestamp":1290988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1741-7015-8-77","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T09:43:49Z","timestamp":1291110229000},"source":"Crossref","is-referenced-by-count":35,"title":["Advances in drug therapy for systemic lupus erythematosus"],"prefix":"10.1186","volume":"8","author":[{"given":"Daniel J","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,29]]},"reference":[{"key":"336_CR1","volume-title":"Dubois' Lupus Erythematosus","year":"2007","unstructured":"Wallace DJ, Hahn BH, (Eds): Dubois' Lupus Erythematosus. 2007, Philadelphia: Lippincott Williams & Wilkins, 7","edition":"7"},{"key":"336_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.7326\/0003-4819-91-4-587","volume":"91","author":"JL Decker","year":"1979","unstructured":"Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH: NIH conference: systemic lupus erythematosus: evolving concepts. Ann Intern Med. 1979, 91: 587-604.","journal-title":"Ann Intern Med"},{"key":"336_CR3","unstructured":"U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus Erythematosus: Developing Drugs for Treatment. Accessed July 28, 2010. Also available at Federal Register 70(59):15868, March 29, 2005, [ http:\/\/www.fda.gov\/ohrms\/dockets\/dockets\/05d01-6\/05d0106.htm ]"},{"key":"336_CR4","unstructured":"U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus Erythematosus: Developing Medical Products for Treatment. Accessed July 28, 2010, [ http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm ]"},{"key":"336_CR5","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1002\/art.22162","volume":"54","author":"CS Yee","year":"2006","unstructured":"Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Bowman S, Maddison P, Zoma A, Allen E, Gordon C, British Isles Lupus Assessment Group: Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006, 54: 3300-3305. 10.1002\/art.22162.","journal-title":"Arthritis Rheum"},{"key":"336_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.2007.077156","volume":"67","author":"SA Wright","year":"2008","unstructured":"Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, Johnston DG, Finch MB, Bell AL, McVeigh GE: A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008, 67: 841-848. 10.1136\/ard.2007.077156.","journal-title":"Ann Rheum Dis"},{"key":"336_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.24068","volume":"59","author":"PR Fortin","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, Canadian Network for Improved Outcomes in Systemic Lupus: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 59: 1796-1804. 10.1002\/art.24068.","journal-title":"Arthritis Rheum"},{"key":"336_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, S\u00e1nchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009, 20: 1103-1112. 10.1681\/ASN.2008101028.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"336_CR9","first-page":"27.","volume":"19","author":"D Wofsy","year":"2010","unstructured":"Wofsy D, Appel GB, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N, Lisk L: Aspreva Lupus Management Study maintenance results. Lupus. 2010, 19 (Suppl): 27..","journal-title":"Lupus"},{"key":"336_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM.S3193","volume":"6","author":"CE Lampropoulos","year":"2010","unstructured":"Lampropoulos CE, D'Cruz DP: Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag. 2010, 6: 95-101. 10.2147\/TCRM.S3193.","journal-title":"Ther Clin Risk Manag"},{"key":"336_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1191\/096120301678416033","volume":"10","author":"CF Remer","year":"2001","unstructured":"Remer CF, Weisman MH, Wallace DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001, 10: 480-483. 10.1191\/096120301678416033.","journal-title":"Lupus"},{"key":"336_CR12","first-page":"1567","volume":"35","author":"J S\u00e1nchez-Guerrero","year":"2008","unstructured":"S\u00e1nchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE: Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008, 35: 1567-1575.","journal-title":"J Rheumatol"},{"key":"336_CR13","first-page":"377","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Burgos-Varagas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Raphupathi K, Peng LT, Kinasczuk M, Nash P: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: results of a 12-month exploratory study. Arthritis Rheum. 2010, 62: 377-387.","journal-title":"Arthritis Rheum"},{"key":"336_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/art.10856","volume":"48","author":"DR Boumpas","year":"2003","unstructured":"Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A: A short course of BG9588 (anti-CD 40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003, 48: 719-727. 10.1002\/art.10856.","journal-title":"Arthritis Rheum"},{"key":"336_CR15","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/art.10681","volume":"46","author":"KC Kalunian","year":"2002","unstructured":"Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46: 3251-3258. 10.1002\/art.10681.","journal-title":"Arthritis Rheum"},{"issue":"S1","key":"336_CR16","first-page":"99","volume":"69","author":"N Czeloth","year":"2010","unstructured":"Czeloth N, Dalken B, Engling A, Osterroth F, Aigner S, Abufarag A, Wartenberg-Demand A, Koch H, Becker C, Jonuleit H, Daniel V, Haefeli WE, Schwarz A, Hass J, Wildemann B, Uherek C: Selective activation of naturally occurring T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity: preclinical and early clinical results. Annals Rheum Dis. 2010, 69 (S1): 99.","journal-title":"Annals Rheum Dis"},{"key":"336_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 222-233. 10.1002\/art.27233.","journal-title":"Arthritis Rheum"},{"key":"336_CR18","first-page":"S429","volume":"60","author":"R Furie","year":"2009","unstructured":"Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J: Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009, 60: S429.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"336_CR19","first-page":"558","volume":"69","author":"D Wallace","year":"2010","unstructured":"Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C: Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Annals Rheum Dis. 2010, 69 (Suppl 3): 558.","journal-title":"Annals Rheum Dis"},{"key":"336_CR20","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 1168-1178. 10.1002\/art.24699.","journal-title":"Arthritis Rheum"},{"key":"336_CR21","unstructured":"Navarra S, Ilianova E, Bae SC, Guzman R, Tanasescu C, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan J, Kim HY, Pineda L, Zhong Z, Freimuth W, Petri M, BLISS-52 Study Group: Belimumab, a BlyS-specific inhibitor reduced disease activity, flares and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Annals Rheum Dis. 2010, 69 (S1)."},{"key":"336_CR22","first-page":"13","volume":"19S","author":"RA Furie","year":"2010","unstructured":"Furie RA, Gladman D, d'Cruz D, Zamani O, Wallace D, von Vollenhoven R, Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guerrero J, Chatham WW, Manzi S, Ginzler E, Mc Kay J, Stohl W, Zhong ZJ, Hough D, Cooper SM, Freimuth W, Petri M, Belimumab : A BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study. Lupus. 2010, 19S: 13.","journal-title":"Lupus"},{"key":"336_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","volume":"48","author":"M Aringer","year":"2009","unstructured":"Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS: Adverse events and efficacy of TNF-\u03b1 blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009, 48: 1451-1454. 10.1093\/rheumatology\/kep270.","journal-title":"Rheumatology (Oxford)"},{"key":"336_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62: 542-552. 10.1002\/art.27221.","journal-title":"Arthritis Rheum"},{"key":"336_CR25","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/art.23673","volume":"58","author":"MH Cardiel","year":"2008","unstructured":"Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP 394-90-09 Investigator Consortium: Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008, 58: 2470-2480. 10.1002\/art.23673.","journal-title":"Arthritis Rheum"},{"key":"336_CR26","unstructured":"Teva Pharmaceutical Industries Ltd.: Press release September 19, 2007. Accessed July 28, 2010, [ http:\/\/www.tevapharm.com\/pr\/2007\/pr_689.asp ]"},{"key":"336_CR27","volume-title":"American College of Rheumatology","author":"M Weinblatt","year":"2009","unstructured":"Weinblatt M, Kavanaugh A, Genovese M, Grossbard E, Magilavy D: Treatment of rheumatoid arthritis (RA) with an oral syk kinase inhibitor: A 6 month randomized placebo controlled phase 2b study in patients with active RA on chronic methotrexate. American College of Rheumatology. 2009, Accessed November 17, 2010, [ http:\/\/acr.confex.com\/acr\/2009\/webprogram\/Paper17160.html ] annual scientific meeting, Abstract LB2"},{"key":"336_CR28","first-page":"1017","volume":"3","author":"M Kaplan","year":"2002","unstructured":"Kaplan M: Eculizumab (Alexion). Curr Opin Investig Drugs. 2002, 3: 1017-1023.","journal-title":"Curr Opin Investig Drugs"},{"key":"336_CR29","first-page":"S526","volume":"56","author":"DJ Wallace","year":"2007","unstructured":"Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, White B: MEDI-545, an anti-interferon \u03b1 monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007, 56: S526.","journal-title":"Arthritis Rheum"},{"key":"336_CR30","first-page":"15","volume":"19S","author":"J Mc Bride","year":"2010","unstructured":"Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M, Jiang J, Drappa J: Safety and pharmacodyamic response with administration of single and repeat doses of rontiluzmab in a phase I, placebo, controlled, double-blind, dose escalation study in SLE. Lupus. 2010, 19S: 15.","journal-title":"Lupus"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-8-77.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-8-77\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-8-77","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T15:29:19Z","timestamp":1468855759000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-8-77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-8-77","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,29]]},"article-number":"77"}}